Department of Neurology, University of Florida, Gainesville, FL, USA.
Department of Anesthesiology, Pain Medicine, University of Florida, Gainesville, FL, USA.
Neuromodulation. 2020 Feb;23(2):234-238. doi: 10.1111/ner.12924. Epub 2019 Feb 14.
Dorsal root ganglion (DRG) stimulation has been demonstrated to be effective in treating painful diabetic polyneuropathy in a small case series. However, diabetic polyneuropathy only accounts for 41% of all polyneuropathies and the efficacy of DRG on other types of polyneuropathy is unclear. The objective of this study is to evaluate the efficacy of DRG stimulation in treating painful hereditary and idiopathic axonal polyneuropathy.
This is a monocentric retrospective case series. Two subjects with painful hereditary axonal polyneuropathy and two subjects with painful chronic idiopathic axonal polyneuropathy who underwent DRG stimulation trials were included in this study. All subjects were evaluated independently by neuromuscular neurologists with eletrophysiological studies and genetic testing. Permanent DRG stimulator was implanted if significant pain relief (>50%) was achieved over the trial period. Pain level were evaluated at baseline, during the trial, after the permanent implantation and at one, three, and six months.
Pain was significantly reduced after the DRG stimulator trial with an average VAS reduction of 6.00 ± 2.83, or 65 ± 26.77% (p = 0.024). Three subjects subsequently underwent permanent DRG stimulator implantation. Pain remained significantly reduced after the permanent implantation. The average VAS reduction was 6.33 ± 2.31, or 67.5 ± 20.46% after permanent DRG implantation (p = 0.042), 7.67 ± 2.31, or 80.83 ± 15.88% at one month (p = 0.029), and 7.00 ± 2.00 or 74.17 ± 14.21% at three and six months (p = 0.026). No complications were observed.
This small retrospective study suggests that DRG stimulation may be a safe and effective treatment for painful hereditary and idiopathic axonal polyneuropathy.
背根神经节(DRG)刺激已被证明在治疗小型病例系列中的痛性糖尿病多发性神经病方面有效。然而,糖尿病多发性神经病仅占所有多发性神经病的 41%,DRG 对其他类型的多发性神经病的疗效尚不清楚。本研究的目的是评估 DRG 刺激治疗痛性遗传性和特发性轴索性多发性神经病的疗效。
这是一项单中心回顾性病例系列研究。纳入了两名接受 DRG 刺激试验的痛性遗传性轴索性多发性神经病患者和两名痛性慢性特发性轴索性多发性神经病患者。所有患者均由神经肌肉神经病学家进行独立评估,包括电生理研究和基因检测。如果在试验期间获得显著的疼痛缓解(>50%),则植入永久性 DRG 刺激器。在基线、试验期间、永久性植入后以及 1、3 和 6 个月时评估疼痛水平。
DRG 刺激器试验后疼痛明显减轻,平均 VAS 评分降低 6.00±2.83,或 65±26.77%(p=0.024)。三名患者随后接受了永久性 DRG 刺激器植入。永久性植入后疼痛仍明显减轻。平均 VAS 评分降低 6.33±2.31,或 67.5±20.46%,永久性 DRG 植入后(p=0.042),7.67±2.31,或 80.83±15.88%,1 个月时(p=0.029),7.00±2.00,或 74.17±14.21%,3 和 6 个月时(p=0.026)。未观察到并发症。
这项小型回顾性研究表明,DRG 刺激可能是治疗痛性遗传性和特发性轴索性多发性神经病的一种安全有效的治疗方法。